Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Amgen Inc.    AMGN

AMGEN INC.

(AMGN)
  Report
Delayed Quote. Delayed Nasdaq - 02/18 04:00:00 pm
221.69 USD   -0.80%
02/14AMGEN INC. : Slide show results
CO
02/14AMGEN INC. : Annual results
CO
02/13AMGEN : Ex-dividend day for
FA
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Amgen Inc.
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:

- drug sales (95%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc. The United States account for 74.5% of net sales;

- other (5%): primarily royalties.
Sales per Businesses
20172018Delta
USD (in Million)%USD (in Million)%
Human Therapeutics21,79595.7%22,53394.8% +3.39%
Other1,0544.6%1,2145.1% +15.18%
Sales per Regions
20172018Delta
USD (in Million)%USD (in Million)%
United States18,02979.1%18,35877.2% +1.82%
Rest of the World4,82021.2%5,38922.7% +11.8%
Managers
NameAgeSinceTitle
Robert Bradway562013Chairman & Chief Executive Officer
Esteban Santos512016Executive Vice President-Operations
Peter H. Griffith602020Chief Financial Officer
David M. Reese, Dr.562018Executive Vice President-Research & Development
Darryl Sleep, Dr.-2018Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian-2001Chief Information Officer & Senior Vice President
Rebecca M. Henderson, Dr.582011Independent Director
Ronald Sugar702011Independent Director
Tyler Jacks, Dr.582012Independent Director
Robert A. Eckert642012Lead Independent Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Stock A 1 589,806,819 588,522,641 99.8% 0 0.0% 99.8%
Shareholders
NameEquities%
Capital Research & Management Co. 71,504,200 12.0%
The Vanguard Group, Inc. 47,468,399 7.99%
Capital Research & Management Co. (Global Investors) 33,594,555 5.65%
SSgA Funds Management, Inc. 25,989,552 4.37%
Fidelity Management & Research Co. 22,397,219 3.77%
PRIMECAP Management Co. 18,200,601 3.06%
BlackRock Fund Advisors 15,022,510 2.53%
NWQ Investment Management Co. LLC 11,762,842 1.98%
Putnam LLC 11,052,604 1.86%
Geode Capital Management LLC 9,925,633 1.67%
Holdings
NameEquities%Valuation
BeiGene, Ltd. (49B) 206,635,01320.6%2,651,953,757 USD
Nuevolution AB 25,257,70151.0%86,265,910 USD
Akero Therapeutics, Inc. (AKRO) 1,905,6986.67%42,296,967 USD
Provention Bio, Inc. (PRVB) 2,500,0005.25%37,250,000 USD
Kezar Life Sciences, Inc. (KZR) 1,121,3845.86%4,496,750 USD
Advaxis, Inc. (ADXS) 203,1640.40%174,315 USD
Markets and indexes
- Nasdaq Stock Market
- Nasdaq Global Select Market
- Nasdaq 100 / SP 100, SP 500, Stoxx Americas 100, Stoxx Global 200, Stoxx NorthAmerica 50, Stoxx USA 50
Stock Exchange Codes
- Bloomberg Code :  AMGN:US
- Reuters Code :  AMGN.O
- Datastream Code :  @AMGN
Company contact information
Amgen Inc.
1 Amgen Center Drive
CA 91320-1799 Thousand Oaks, California
États-Unis (les)

Phone : +1 805 447 1000
Fax : +1 805 447 1010
Internet : http://www.amgen.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Amgen Inc.
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
AMGEN INC.-7.30%130 754
JOHNSON & JOHNSON2.92%392 517
ROCHE HOLDING AG8.47%299 201
NOVARTIS4.05%220 283
MERCK AND COMPANY-9.33%209 942
PFIZER-6.81%200 999
NOVO NORDISK AS12.78%150 539
BRISTOL-MYERS SQUIBB COMPANY3.41%148 724
ABBVIE INC.5.73%138 432
ELI LILLY AND COMPANY7.29%135 388
ASTRAZENECA PLC-1.13%128 554
SANOFI4.56%127 105
GLAXOSMITHKLINE-6.30%108 063
BAYER AG3.30%79 931
ALLERGAN PLC3.74%64 999
TAKEDA PHARMACEUTICAL COMPANY LIMITED-2.12%59 675
CHUGAI PHARMACEUTICAL CO., LTD.17.35%58 521
JIANGSU HENGRUI MEDICINE CO., LTD.4.60%57 020
DAIICHI SANKYO COMPANY, LIMITED5.24%44 422
ASTELLAS PHARMA INC.1.00%31 644
EISAI CO., LTD.8.53%22 899